Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 11,405 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Cocaine-Related Disorders
Interventions: Selegiline; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 16
States / cities: Tucson, Arizona • Berkeley, California • Los Angeles, California + 11 more

Conditions: Hemophilia A
Interventions: Emicizumab; Biological
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years and older
U.S. locations: 14
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 11 more

Conditions: Breast Cancer
Interventions: Automated message, Opt-out scheduling; Other
Lead sponsor: VA Puget Sound Health Care System; Federal
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: mavacamten, Placebo; Drug
Lead sponsor: MyoKardia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Seattle, Washington

Conditions: Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Interventions: Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 3 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more

Conditions: Prostate Cancer
Interventions: External beam radiation, Pd-103; Procedure
Lead sponsor: Schiffler Cancer Center; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 2
States / cities: Seattle, Washington • Wheeling, West Virginia

Conditions: Cognition Disorders, HIV Infections
Interventions: Selegiline hydrochloride; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more

Conditions: Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome
Interventions: Genetic Testing for PCD or PID, Unaffected Family Member Genetic Testing; Diagnostic Test · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 5 Years to 45 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Palo Alto, California • Aurora, Colorado • Bethesda, Maryland + 3 more

Conditions: Ulcerative Colitis (UC)
Interventions: Upadacitinib (ABT-494), Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 147
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more

Conditions: HIV Infections
Interventions: Tumor Necrosis Factor, Interferon gamma-1b; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Ketoconazole, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 41
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more

Conditions: Parkinson's Disease
Interventions: Standard of Care; Other
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more

Conditions: Lung Cancer
Interventions: bevacizumab, pemetrexed disodium; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 248
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Little Rock, Arkansas + 161 more

Conditions: Neuroblastoma
Interventions: Gene panel sequencing of tumor specimens; Other
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 30 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Benign Prostatic Hypertrophy
Interventions: Cetrorelix Pamoate; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 56
States / cities: Homewood, Alabama • Huntsville, Alabama • Laguna Hills, California + 49 more

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 20
States / cities: Harbor City, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Prostate Cancer
Interventions: Atrasentan; Drug
Lead sponsor: Abbott; Industry
Eligibility: 19 Years and older · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 79
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 66 more

Conditions: Pain, Postoperative
Interventions: Educational Video; Behavioral
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anal Cancer, Precancerous Condition
Interventions: cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination; Drug · Genetic · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: PTCH1 or SMO Activated Solid and Hematologic Tumors
Interventions: LDE225; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Sacramento, California • Greenwood Village, Colorado • Chicago, Illinois + 6 more

Conditions: Liver Cirrhosis, Biliary
Interventions: Methotrexate; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 20 Years to 69 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2004
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more

Conditions: Plaque Psoriasis
Interventions: Ixekizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 59
States / cities: Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 52 more

Conditions: Atherosclerosis, Coronary Artery Disease
Interventions: Percutaneous coronary intervention (Promus PREMIER); Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 52
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 48 more

Search by objective public record fields.

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Opt-in vs. Opt-out for Breast Cancer Screening

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Neuroblastoma Precision Trial

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Do Patient Educational Videos Improve Pain and Recovery After Laparoscopic Hysterectomy?

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

LDE225 for Patients With PTCH1 or SMO Mutated Tumors

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

PLATINUM Diversity